Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDER-Only Reviews Increase For Combination Products With Stand-Alone Devices, But Issues Remain

Executive Summary

Trend has emerged in last two or three years, but attorney says sponsors also have to be careful about ensuring one center maintains control of the review.

You may also be interested in...

Califf Supports Combo Products Pathway At Confirmation Hearing

FDA's concepts for new pathway could be ready for congressional scrutiny within a year.

Will Combination Products Join The User Fee Family?

Joint drug and device negotiations for combination products, separate performance goals, or maybe a separate pathway have been discussed.

House Trims 21st Century Cures Fat: Draft Bill Loses Half Its Weight

New discussion draft drops controversial exclusivity extensions and some other lesser-known ideas that may have benefited FDA and sponsors, but some placeholders still need to be filled.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts